Enveric Biosciences Inc. (ENVB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.43 (-2.06% 1D, market cap $6.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ENVB ranks #654 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).
Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $24.6M in revenue (-8.9% YoY), $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 48.2 (NEUTRAL RANGE)
Capital intensity & 0% operating margin leave 16 pts on the table
While ENVB currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.46) and Max Pain ($1.50) forces dealer call-delta covering toward $13.91.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Enveric Biosciences Inc. (ENVB) dropped -2.06% to $1.43, trading at 2% of its 52-week range ($1.17 – $13.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -8.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ENVB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ENVB. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Enveric Biosciences Inc. (ENVB) ranks #654 by composite RQD confidence (34/100, grade E) and #923 by equity capitalization ($6.4M). Within this direct 5-issuer industry benchmark cohort, ENVB leads on earnings valuation at N/A trailing P/E, while ENVB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ENVB at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENVB
ACTIVE
Enveric Biosciences Inc. | E | 34/100 | — | — | -35.0% | -2.06% | $6.4M | Benchmark Subject |
| FBLG FibroBiologics Inc. | D- | 36/100 | — | — | -35.0% | +0.21% | $6.3M | /fblg-vs-envb → |
| XCUR Exicure Inc. | E | 32/100 | — | — | -35.0% | +8.05% | $6.6M | /xcur-vs-envb → |
| APRE Aprea Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -1.82% | $6.1M | /apre-vs-envb → |
| BGMS Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | +8.43% | $6.0M | /bgms-vs-envb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enveric Biosciences Inc. (ENVB) reported GAAP revenue of $24.6M (-8.9% vs. FY2024 revenue of $27.0M , and -46.7% cumulative change since FY2023) , GAAP net income of $12.1M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-5.4% YoY). On the balance sheet, ENVB closed FY2025 with $5.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $24.6M | $12.1M | -$8.1M | -$8.1M | $5.1M | — |
| FY2024 (FY) | 2024-12-31 | $27.0M | $9.6M | -$7.7M | -$7.7M | $3.1M | — |
| FY2023 (FY) | 2023-12-31 | $46.1M | $17.5M | -$14.1M | -$14.1M | — | — |
As of 2026-11-03, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.43 (-2.06% 1D, market cap $6.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ENVB ranks #654 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).
Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $24.6M in revenue (-8.9% YoY), $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ENVB last traded at $1.43 (-2.06% on volume of 12,003 shares), positioning the stock -2.05% below its 50-day simple moving average ($1.46) and -28.14% below its 200-day simple moving average ($1.99). Across its 52-week range of $1.17 to $13.25, ENVB sits at the 2.2% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).
Enveric Biosciences Inc. (ENVB) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.43 (-2.06% 1D, market capitalization $6.4M).
Enveric Biosciences Inc. (ENVB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company operates as a biotechnology issuer.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Enveric Biosciences Inc. (ENVB) reported $24.6M in annual revenue (up from $27.0M in FY2024, -8.9% YoY) and $12.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.1M revenue, $17.5M net income) through FY2025, ENVB scaled operating cash flow to -$8.1M and free cash flow to -$8.1M, backed by $5.1M in total assets against $0 in total debt.
There are no upstream or downstream links, no sector-correlation links, and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Enveric Biosciences Inc. (ENVB) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in ENVB in my $100K Virtual Cash book at $1.43. Recent news wire items report favorable preclinical results and positive IND-enabling ADMET study outcomes for a psychiatric candidate.. Trading inside a $1.17–$13.25 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
ROIC of -35% and 0% FCF yield, with negative operating income in every reported period, show no current cash generation to support the valuation.. Look at the math on ENVB: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.26 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).